Nuformix plc (LON:NFX – Get Free Report)’s stock price dropped 10.7% during mid-day trading on Wednesday . The stock traded as low as GBX 0.18 and last traded at GBX 0.18. 3,820,803 shares traded hands during trading, a decline of 90% from the average session volume of 37,000,402 shares. The stock had previously closed at GBX 0.20.
Nuformix Price Performance
The business has a 50-day simple moving average of GBX 0.18 and a 200 day simple moving average of GBX 0.22. The firm has a market cap of £4.96 million, a PE ratio of -6.48 and a beta of 1.54.
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) earnings per share for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Articles
- Five stocks we like better than Nuformix
- Buyback Capacity Is Rising Across 3 Soaring and Sinking Stocks
- How to Invest in the Biggest European Defense Surge in Decades
- The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
